Combination Antibiotic Therapy for Staph Bacteremia

(COMBAT-SAB Trial)

This trial examines the effectiveness of a combination of antibiotics versus a single antibiotic in treating serious blood infections caused by specific bacteria. It focuses on patients with either methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant Staphylococcus aureus (MRSA), both of which can cause these infections. Participants will receive either one antibiotic or a combination to determine which method is more effective. Patients diagnosed with a Staph infection in the blood while staying at an Intermountain Health hospital may be suitable for this study. As a Phase 4 trial, the treatment is already FDA-approved and proven effective, aiming to understand its benefits for more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that using a combination of antibiotics for methicillin-sensitive Staphylococcus aureus bacteremia (MSSAB) might not reduce the risk of death. However, it may increase the likelihood of side effects, such as drug reactions and kidney issues. This indicates that while the treatment might not significantly reduce mortality from the infection, it could lead to more side effects.

For methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), studies suggest that a combination of antibiotics could lower the risk of death compared to a single antibiotic. This is promising, but using multiple antibiotics can sometimes cause side effects.

Researchers are excited about combination antibiotic therapy for Staph bacteremia because it offers a potential edge over the standard monotherapy. For patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and methicillin-resistant S. aureus bacteremia (MRSAB), this approach uses a strategic mix of antibiotics, which could enhance effectiveness by attacking the bacteria from multiple angles. This method might improve outcomes by reducing treatment failure rates and preventing the development of antibiotic resistance. Unlike standard treatments that typically rely on a single antibiotic, combination therapy could provide a more robust defense against these tough infections.

Research shows that a combination of antibiotics works differently depending on the type of Staphylococcus aureus blood infection. In this trial, participants with methicillin-sensitive S. aureus bacteremia (MSSAB) will receive either antibiotic monotherapy or combination antibiotic therapy. Studies have found that using more than one antibiotic for MSSAB did not reduce death rates and even increased the chance of side effects. Meanwhile, participants with methicillin-resistant S. aureus bacteremia (MRSAB) will also receive either monotherapy or combination therapy. Evidence suggests that a combination of antibiotics for MRSAB can lower death rates compared to monotherapy, indicating that combining antibiotics might be more effective specifically for treating MRSAB.¹²³⁴⁶